Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Completed · Phase 2
Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
In brief
The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
Key facts
- Study ID
- NCT00974233
- Run by
- University of Wisconsin, Madison
- People needed
- 34
- Starts
- 2009-10-01
- Expected to finish
- 2015-04-01
- Last updated by the study team
- 2019-12-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed,CLL/SLL, documented relapsed or refractory disease after at least one prior chemotherapy regimen.
- In cases of SLL, patients must have at least one bidimensionally measurable lesion at least ≥1.5 cm measured in one dimension.
- ECOG performance status of 0-2 at study entry
- Laboratory test results within these ranges: ANC <=1500/μL, Platelet count <= 100,000/μL. Patients with ANC <1500/μL or plt <100,000/μL with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligible.
- creatinine clearance of >60 mL/min as determined by the Cockcroft-Gault calculation.
- Total bilirubin <= 2X upper limit laboratory normal (ULN). Patients with non-clinically significant elevations of bilirubin due to Gilbert's disease are not required to meet these criteria.
- Serum transaminases AST (SGOT) and ALT (SGPT) <=5x ULN, Serum alkaline phosphatase ≤5 X ULN.
- Disease free of prior malignancies for ≥ 2 years with the exception of basal or squamous cell skin carcinoma, carcinoma "in situ" of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery).
- Patients may have received prior therapy with bendamustine or lenalidomide, but must not have disease that is refractory to bendamustine or lenalidomide.
- Prior therapy with rituximab is permitted, even in the setting of rituximab refractory disease.
You may not qualify if…
- Has received >5 lines of prior therapy for their disease. Re-treatment with an identical regimen does not count as a new regimen.
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form or comply with the protocol treatment.
- Pregnant or breast feeding females. Lactating females must agree not to breast feed while taking lenalidomide.
- Prior history or current evidence of central nervous system or leptomeningeal involvement.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Known hypersensitivity to thalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Known to be positive for HIV or infectious hepatitis, type B or C.
Where it is running
- St Vincent Regional Cancer Center — Green Bay, Wisconsin, United States
- Bellin Memorial Hospital — Green Bay, Wisconsin, United States
- Mercy Health System Heme/Onc — Janesville, Wisconsin, United States
- Gundersen Clinic — La Crosse, Wisconsin, United States
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States
- Marshfield Clinic — Marshfield, Wisconsin, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Oconomowoc Memorial Hospital — Oconomowoc, Wisconsin, United States
- Waukesha Memorial Hospital — Waukesha, Wisconsin, United States
- Riverview Hospital — Wisconsin Rapids, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.